Bio-Rad Laboratories Inc (BIO, Financial) is set to release its Q2 2024 earnings on Aug 1, 2024. The consensus estimate for Q2 2024 revenue is $645.79 million, and the earnings are expected to come in at $2.13 per share. The full year 2024's revenue is expected to be $2.65 billion and the earnings are expected to be $10.14 per share. More detailed estimate data can be found here.
Bio-Rad Laboratories Inc (BIO, Financial) Estimate Trends
Over the past 90 days, revenue estimates for Bio-Rad Laboratories Inc (BIO) have declined from $2.69 billion to $2.65 billion for the full year 2024, and from $2.82 billion to $2.79 billion for 2025. Earnings estimates have also been revised downward from $10.96 per share to $10.14 per share for the full year 2024, and from $12.38 per share to $11.45 per share for 2025.
Bio-Rad Laboratories Inc (BIO, Financial) Reported History
In the previous quarter of March 31, 2024, Bio-Rad Laboratories Inc's (BIO) actual revenue was $610.82 million, which missed analysts' revenue expectations of $619.09 million by -1.34%. Bio-Rad Laboratories Inc's (BIO) actual earnings were $13.45 per share, which beat analysts' earnings expectations of $2.29 per share by 487.34%. After releasing the results, Bio-Rad Laboratories Inc (BIO) was down by -4.16% in one day.
Bio-Rad Laboratories Inc (BIO, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 5 analysts, the average target price for Bio-Rad Laboratories Inc (BIO) is $343.40 with a high estimate of $402 and a low estimate of $300. The average target implies an upside of 0.92% from the current price of $340.26.
Based on GuruFocus estimates, the estimated GF Value for Bio-Rad Laboratories Inc (BIO, Financial) in one year is $476.47, suggesting an upside of 40.03% from the current price of $340.26.
Based on the consensus recommendation from 6 brokerage firms, Bio-Rad Laboratories Inc's (BIO, Financial) average brokerage recommendation is currently 2.7, indicating a "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
